Regeneration difficulties in patients with FQAD can limit the use of iPSc-based cell therapy

Stem Cell Research & Therapy

Tomasz P. Ochedalski¹  Ewelina Stoczynska-Fidelus²  Katarzyna Wasiak²  Piotr Rieske³  Dagmara Grot³  Jerzy Tyszkowski⁴ 

[1] Department of Comparative Endocrinology, Medical University of Lodz;Department of Research and Development, Personather Ltd.;Department of Tumor Biology, Medical University of Lodz;Fluoroquinolone Toxicity Study NFP;

关键词: Fluoroquinolones;    FQAD;    Induced pluripotent stem cells;    Reprogramming;   

DOI  :  10.1186/s13287-022-02886-0

来源: DOAJ

【 摘 要 】

Abstract Etiopathogenesis of fluoroquinolone-associated disability (FQAD) syndrome is not fully understood, yet research could progress by utilizing induced pluripotent stem cells (iPSc) from people with this syndrome. Similarly, iPSc, or rather their derivatives, could be used in their therapy, not only for FQAD but also for other disorders in which generated autologous iPSc and their derivatives might be helpful. Urine was collected from ten donors with FQAD, and reprogramming of these cells was conducted with the use of Epi5TM Episomal iPSC Reprogramming Kit. IPSc were generated in one out of ten person’s urine cells. While urinary cells are considered the easiest mature cells to be reprogrammed into iPSc, the urinary cells from six consecutive donors quickly became senescent. Stable urine primary cell cultures could not be obtained from the three remaining donors. Repeated attempts to reprogram epithelial cells were not successful. During parallel studies conducted for healthy donors, reprogramming success was achieved in six out of ten cases. These data may suggest serious limitations in the regeneration system of individuals with FQAD. Consequently, it indicates that therapy with autologous iPSc derivatives may face serious difficulties in their case, still, the first iPSc cell line from a person with FQAD was established.

【 授权许可】

Unknown